Humana Trades at 5.7x Earnings and Holds $4.2B Cash Position
Humana trades near 5.7x normalized earnings and about 2.5x operating cash flow following 10% annual revenue growth and holds $4.2 billion in cash against $4.3 billion debt. Bull case assumes CMS rate cuts will be phased gradually, sustaining 3–4% margins and potentially driving a re-rating toward $260–300 over 12–18 months.
1. Valuation Discount
At roughly $176 per share, Humana trades at 5.7x normalized earnings and about 2.5x operating cash flow despite delivering 10% annual revenue growth, reflecting a significant cyclical discount driven by investor concerns over Medicare Advantage reimbursement pressure.
2. Financial Strength
Operating cash flow exceeded net income by $1.1 billion last year, and the company holds $4.2 billion in cash against $4.3 billion of debt, highlighting conservative reserving and limited downside risk under adverse scenarios.
3. Regulatory Outlook and Catalysts
Key upcoming catalysts include 2026 earnings revealing margin trends, 2027 rate announcements, Star Ratings updates, and enrollment data, while gradual CMS rate cuts and Humana's scaled position in Medicare Advantage may sustain margin stability.
4. Risks and Upside Scenarios
Bearish scenarios anticipate sustained 3–4% margins valuing the stock at $220–250, while normalization of medical cost ratios and clearer rate visibility could drive upside to $260–300 or higher, balancing risk of regulatory tightening against asymmetric reward potential.